2025 Q4 -tulosraportti
Vain PDF
98 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenConsidering the development last 6 months Isn't the stock okay possibly 1-2 down 1/2 up, Is there any reason for it to rise without anything other than hope faith and good prospects? And why do so many react to up 1 kr down 1,50.? This is a money grab. If you are sitting on 100.000 /500.000 shares, why not be active? To all experts, is it stagnant kr or kr in circulation that generates best? Just wondering? I don't have 100.000 or more far from it, but have nevertheless generated an okay profit last 12 weeks. It has been pushed into new shares, which has resulted in an okay % increase in the number of shares. If this little amateur can have that understanding, what do you think the sharks do? Sit still in the boat? And the excessive hype, ( both ways) why? I naturally have a good feeling, and right now we know that we own a share at kr 8,63 neither more nor less. But we wish and believe there is something more to come. Anyway, wishing everyone a continued good summer😎Yes absolutely, now you are also not someone I have seen as very active on either + or - comments, ( from what I can say not having seen the name ) in contrast to 20-30 pcs. who are at such a professionally high level that I find it strange they are here. The point was the noise that is made about this stock being sold when one has first bought it. Then we have some who label us as idiots/cowards/low understanding etc. If everyone locks down each stock until past 20-25-30 The total value creation will probably be significantly lower than active trading. As volatility has been high, I think quite a few who are actively involved in this with large positions utilize buying and selling. I would have been more active if time and if the interest in making the increase of the stock position had meant everything. But 1500-3/4000 new shares on certain days becomes a bit silly not to take. Have other Invest. that I don't sacrifice, at the same time I'm not interested in dropping out, this is in my opinion a good opportunity. If not all roads lead to Gold (Rome), then several do. Ultimately this is A Money Grab And everyone must choose for themselves how they think they do it best. Then we hope that everyone ends up with a result they are satisfied with. Without anyone being imbisie idiots one way or the other. 😉
·9 t sittenHas the market woken up? The price has shown increased strength recently, and it seems interest is returning. After the common holiday period, we enter a period where many expect continuous news, what's the gut feeling in the short term?26 ääntä 1 päivä 14 tuntia jäljelläLiity Nordnet Socialiin osallistuaksesi kyselyyn
·10 t sittenIngress (BioWorld – July 21, 2026): To viral or not to viral: In vivo CAR T debates delivery tech The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution. The industrial shift: From autologous cell factory to off-the-shelf product Today's CAR-T treatment is a logistical and production bottleneck. The process of extracting a patient's own T-cells, genetically modifying them ex vivo, and returning them to the hospital costs up to 500,000 USD per patient and takes weeks. The debate at BIO Asia-Taiwan 2026 confirms a paradigm shift: The industry is moving towards in vivo CAR-T, where the genetic code is delivered directly into the body via vectors or lipid nanoparticles (LNPs) to reprogram T-cells in the bloodstream. The discussion is about scalability, biological effect, and durability without permanent genomic integration. When experts refer to this as CAR-T's "second revolution", it signals that the next chapter will be determined by RNA design, expression time, and delivery architecture. Why RNA is the engine – and why Circio is in the current In issue after issue of BioWorld, capital and research converge around one problem: How to create powerful biological activity in the body without permanent integration into the genome? For in vivo programming, the industry desires non-integrating solutions but encounters challenges related to durability. Traditional linear mRNA degrades relatively quickly, which limits expression time compared to circular RNA constructs. This is where circular RNA (circRNA) and the circVec platform become particularly relevant: • Degradation protection: Closing the ends of the RNA molecule protects against enzymatic degradation. • Extended window: Provides more sustained protein expression and higher biological activity per dose over time. The conferences in 2026 are dominated by demands for durability, persistence, in vivo delivery, and stable protein production. The direction the market is moving points directly into the technological space Circio operates in. CASE 2: Spinal cord, brain, and precision chemistry in CNS therapy Ingress (BioWorld – July 21, 2026): RAG-17 silences SOD1, extends survival in ALS preclinical models Because mutant SOD1 drives amyotrophic lateral sclerosis (ALS) through a toxic gain-of-function mechanism, suppression of SOD1 expression is considered a promising disease-modifying approach. Researchers from Ractigen Therapeutics Co. Ltd. described the preclinical profile of RAG-17, an siRNA therapy designed to knockdown the expression of SOD1, conjugated to a smart chemistry aided delivery (SCAD) system for enhanced CNS delivery via intrathecal injection. Point A: Targeted silencing in the central nervous system (CNS) Ractigen's study uses siRNA linked to a proprietary delivery system for CNS distribution. By knocking down gene expression before the toxic protein is produced in ALS, the source of the disease is attacked. Extended survival and reduction of the damage marker NfL support that RNA therapies are increasingly becoming a central treatment strategy in neurology. Point B: The delivery bottleneck in CNS – why stable platforms win The challenge in CNS is to achieve sufficient biological activity in the right place, for long enough: • Delivery is value. • Durability is value. • Effective biological activity is value. Point C: The race accelerates When FAST on the same day awards funding to Nobel laureate Frances Arnold for RNA tools in the brain, it confirms that Big Pharma, biotech companies, and top researchers are simultaneously pursuing the same solutions. Summary: Autumn's news queue and focus on Circio Today's BioWorld cases point to the biological themes Circio has built its platform around: in vivo therapy, extended expression, demanding CNS delivery, and non-integrating RNA with high activity. With preclinical data showing up to 50x increased expression in the eye and 40x in the heart, as well as an active in vivo collaboration with a top-5 pharma partner in CNS, Circio's news drivers are at the intersection of these global trends. The key going forward is about who delivers the highest activity and longest expression in the tissue. It is at this intersection that the circVec platform is positioned. It is also here that several of autumn's expected data points are anticipated to give the market a better understanding of the platform's potential.
Love getting such professional and good input! Excellent, yes! This case might eventually be a Nobel Prize? No negative "results" per Erik until 2030! What happens until then!? Was also enthusiastic about Aker Horizone…. This is so incredibly exciting. Still in the red, yes, but I've thoroughly familiarized myself with Circio, plus over 20 years in a pharmaceutical company, so …
·13 t sittenIt's been a long time since such a sell-side/post has been seen at close. It must be said to be impressive that it's doing so well here in the middle of the holiday season. I have invested in many companies/stocks, but rarely have I been in such an exciting case. It's absolutely wild how many strings they have to play on. My estimate when the week is over is approx 10kr. But I have been wrong before. Good luck to you all.
I bet when it gets up to 9 again, one will realize that the sentiment has shifted and the uptrend is lasting. Eventually, we will probably also get some FOMO boost, as most know that this could quickly be 10 the year's case that materializes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
98 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenConsidering the development last 6 months Isn't the stock okay possibly 1-2 down 1/2 up, Is there any reason for it to rise without anything other than hope faith and good prospects? And why do so many react to up 1 kr down 1,50.? This is a money grab. If you are sitting on 100.000 /500.000 shares, why not be active? To all experts, is it stagnant kr or kr in circulation that generates best? Just wondering? I don't have 100.000 or more far from it, but have nevertheless generated an okay profit last 12 weeks. It has been pushed into new shares, which has resulted in an okay % increase in the number of shares. If this little amateur can have that understanding, what do you think the sharks do? Sit still in the boat? And the excessive hype, ( both ways) why? I naturally have a good feeling, and right now we know that we own a share at kr 8,63 neither more nor less. But we wish and believe there is something more to come. Anyway, wishing everyone a continued good summer😎Yes absolutely, now you are also not someone I have seen as very active on either + or - comments, ( from what I can say not having seen the name ) in contrast to 20-30 pcs. who are at such a professionally high level that I find it strange they are here. The point was the noise that is made about this stock being sold when one has first bought it. Then we have some who label us as idiots/cowards/low understanding etc. If everyone locks down each stock until past 20-25-30 The total value creation will probably be significantly lower than active trading. As volatility has been high, I think quite a few who are actively involved in this with large positions utilize buying and selling. I would have been more active if time and if the interest in making the increase of the stock position had meant everything. But 1500-3/4000 new shares on certain days becomes a bit silly not to take. Have other Invest. that I don't sacrifice, at the same time I'm not interested in dropping out, this is in my opinion a good opportunity. If not all roads lead to Gold (Rome), then several do. Ultimately this is A Money Grab And everyone must choose for themselves how they think they do it best. Then we hope that everyone ends up with a result they are satisfied with. Without anyone being imbisie idiots one way or the other. 😉
- ·9 t sittenHas the market woken up? The price has shown increased strength recently, and it seems interest is returning. After the common holiday period, we enter a period where many expect continuous news, what's the gut feeling in the short term?26 ääntä 1 päivä 14 tuntia jäljelläLiity Nordnet Socialiin osallistuaksesi kyselyyn
- ·10 t sittenIngress (BioWorld – July 21, 2026): To viral or not to viral: In vivo CAR T debates delivery tech The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution. The industrial shift: From autologous cell factory to off-the-shelf product Today's CAR-T treatment is a logistical and production bottleneck. The process of extracting a patient's own T-cells, genetically modifying them ex vivo, and returning them to the hospital costs up to 500,000 USD per patient and takes weeks. The debate at BIO Asia-Taiwan 2026 confirms a paradigm shift: The industry is moving towards in vivo CAR-T, where the genetic code is delivered directly into the body via vectors or lipid nanoparticles (LNPs) to reprogram T-cells in the bloodstream. The discussion is about scalability, biological effect, and durability without permanent genomic integration. When experts refer to this as CAR-T's "second revolution", it signals that the next chapter will be determined by RNA design, expression time, and delivery architecture. Why RNA is the engine – and why Circio is in the current In issue after issue of BioWorld, capital and research converge around one problem: How to create powerful biological activity in the body without permanent integration into the genome? For in vivo programming, the industry desires non-integrating solutions but encounters challenges related to durability. Traditional linear mRNA degrades relatively quickly, which limits expression time compared to circular RNA constructs. This is where circular RNA (circRNA) and the circVec platform become particularly relevant: • Degradation protection: Closing the ends of the RNA molecule protects against enzymatic degradation. • Extended window: Provides more sustained protein expression and higher biological activity per dose over time. The conferences in 2026 are dominated by demands for durability, persistence, in vivo delivery, and stable protein production. The direction the market is moving points directly into the technological space Circio operates in. CASE 2: Spinal cord, brain, and precision chemistry in CNS therapy Ingress (BioWorld – July 21, 2026): RAG-17 silences SOD1, extends survival in ALS preclinical models Because mutant SOD1 drives amyotrophic lateral sclerosis (ALS) through a toxic gain-of-function mechanism, suppression of SOD1 expression is considered a promising disease-modifying approach. Researchers from Ractigen Therapeutics Co. Ltd. described the preclinical profile of RAG-17, an siRNA therapy designed to knockdown the expression of SOD1, conjugated to a smart chemistry aided delivery (SCAD) system for enhanced CNS delivery via intrathecal injection. Point A: Targeted silencing in the central nervous system (CNS) Ractigen's study uses siRNA linked to a proprietary delivery system for CNS distribution. By knocking down gene expression before the toxic protein is produced in ALS, the source of the disease is attacked. Extended survival and reduction of the damage marker NfL support that RNA therapies are increasingly becoming a central treatment strategy in neurology. Point B: The delivery bottleneck in CNS – why stable platforms win The challenge in CNS is to achieve sufficient biological activity in the right place, for long enough: • Delivery is value. • Durability is value. • Effective biological activity is value. Point C: The race accelerates When FAST on the same day awards funding to Nobel laureate Frances Arnold for RNA tools in the brain, it confirms that Big Pharma, biotech companies, and top researchers are simultaneously pursuing the same solutions. Summary: Autumn's news queue and focus on Circio Today's BioWorld cases point to the biological themes Circio has built its platform around: in vivo therapy, extended expression, demanding CNS delivery, and non-integrating RNA with high activity. With preclinical data showing up to 50x increased expression in the eye and 40x in the heart, as well as an active in vivo collaboration with a top-5 pharma partner in CNS, Circio's news drivers are at the intersection of these global trends. The key going forward is about who delivers the highest activity and longest expression in the tissue. It is at this intersection that the circVec platform is positioned. It is also here that several of autumn's expected data points are anticipated to give the market a better understanding of the platform's potential.Love getting such professional and good input! Excellent, yes! This case might eventually be a Nobel Prize? No negative "results" per Erik until 2030! What happens until then!? Was also enthusiastic about Aker Horizone…. This is so incredibly exciting. Still in the red, yes, but I've thoroughly familiarized myself with Circio, plus over 20 years in a pharmaceutical company, so …
- ·13 t sittenIt's been a long time since such a sell-side/post has been seen at close. It must be said to be impressive that it's doing so well here in the middle of the holiday season. I have invested in many companies/stocks, but rarely have I been in such an exciting case. It's absolutely wild how many strings they have to play on. My estimate when the week is over is approx 10kr. But I have been wrong before. Good luck to you all.I bet when it gets up to 9 again, one will realize that the sentiment has shifted and the uptrend is lasting. Eventually, we will probably also get some FOMO boost, as most know that this could quickly be 10 the year's case that materializes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
98 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenConsidering the development last 6 months Isn't the stock okay possibly 1-2 down 1/2 up, Is there any reason for it to rise without anything other than hope faith and good prospects? And why do so many react to up 1 kr down 1,50.? This is a money grab. If you are sitting on 100.000 /500.000 shares, why not be active? To all experts, is it stagnant kr or kr in circulation that generates best? Just wondering? I don't have 100.000 or more far from it, but have nevertheless generated an okay profit last 12 weeks. It has been pushed into new shares, which has resulted in an okay % increase in the number of shares. If this little amateur can have that understanding, what do you think the sharks do? Sit still in the boat? And the excessive hype, ( both ways) why? I naturally have a good feeling, and right now we know that we own a share at kr 8,63 neither more nor less. But we wish and believe there is something more to come. Anyway, wishing everyone a continued good summer😎Yes absolutely, now you are also not someone I have seen as very active on either + or - comments, ( from what I can say not having seen the name ) in contrast to 20-30 pcs. who are at such a professionally high level that I find it strange they are here. The point was the noise that is made about this stock being sold when one has first bought it. Then we have some who label us as idiots/cowards/low understanding etc. If everyone locks down each stock until past 20-25-30 The total value creation will probably be significantly lower than active trading. As volatility has been high, I think quite a few who are actively involved in this with large positions utilize buying and selling. I would have been more active if time and if the interest in making the increase of the stock position had meant everything. But 1500-3/4000 new shares on certain days becomes a bit silly not to take. Have other Invest. that I don't sacrifice, at the same time I'm not interested in dropping out, this is in my opinion a good opportunity. If not all roads lead to Gold (Rome), then several do. Ultimately this is A Money Grab And everyone must choose for themselves how they think they do it best. Then we hope that everyone ends up with a result they are satisfied with. Without anyone being imbisie idiots one way or the other. 😉
- ·9 t sittenHas the market woken up? The price has shown increased strength recently, and it seems interest is returning. After the common holiday period, we enter a period where many expect continuous news, what's the gut feeling in the short term?26 ääntä 1 päivä 14 tuntia jäljelläLiity Nordnet Socialiin osallistuaksesi kyselyyn
- ·10 t sittenIngress (BioWorld – July 21, 2026): To viral or not to viral: In vivo CAR T debates delivery tech The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution. The industrial shift: From autologous cell factory to off-the-shelf product Today's CAR-T treatment is a logistical and production bottleneck. The process of extracting a patient's own T-cells, genetically modifying them ex vivo, and returning them to the hospital costs up to 500,000 USD per patient and takes weeks. The debate at BIO Asia-Taiwan 2026 confirms a paradigm shift: The industry is moving towards in vivo CAR-T, where the genetic code is delivered directly into the body via vectors or lipid nanoparticles (LNPs) to reprogram T-cells in the bloodstream. The discussion is about scalability, biological effect, and durability without permanent genomic integration. When experts refer to this as CAR-T's "second revolution", it signals that the next chapter will be determined by RNA design, expression time, and delivery architecture. Why RNA is the engine – and why Circio is in the current In issue after issue of BioWorld, capital and research converge around one problem: How to create powerful biological activity in the body without permanent integration into the genome? For in vivo programming, the industry desires non-integrating solutions but encounters challenges related to durability. Traditional linear mRNA degrades relatively quickly, which limits expression time compared to circular RNA constructs. This is where circular RNA (circRNA) and the circVec platform become particularly relevant: • Degradation protection: Closing the ends of the RNA molecule protects against enzymatic degradation. • Extended window: Provides more sustained protein expression and higher biological activity per dose over time. The conferences in 2026 are dominated by demands for durability, persistence, in vivo delivery, and stable protein production. The direction the market is moving points directly into the technological space Circio operates in. CASE 2: Spinal cord, brain, and precision chemistry in CNS therapy Ingress (BioWorld – July 21, 2026): RAG-17 silences SOD1, extends survival in ALS preclinical models Because mutant SOD1 drives amyotrophic lateral sclerosis (ALS) through a toxic gain-of-function mechanism, suppression of SOD1 expression is considered a promising disease-modifying approach. Researchers from Ractigen Therapeutics Co. Ltd. described the preclinical profile of RAG-17, an siRNA therapy designed to knockdown the expression of SOD1, conjugated to a smart chemistry aided delivery (SCAD) system for enhanced CNS delivery via intrathecal injection. Point A: Targeted silencing in the central nervous system (CNS) Ractigen's study uses siRNA linked to a proprietary delivery system for CNS distribution. By knocking down gene expression before the toxic protein is produced in ALS, the source of the disease is attacked. Extended survival and reduction of the damage marker NfL support that RNA therapies are increasingly becoming a central treatment strategy in neurology. Point B: The delivery bottleneck in CNS – why stable platforms win The challenge in CNS is to achieve sufficient biological activity in the right place, for long enough: • Delivery is value. • Durability is value. • Effective biological activity is value. Point C: The race accelerates When FAST on the same day awards funding to Nobel laureate Frances Arnold for RNA tools in the brain, it confirms that Big Pharma, biotech companies, and top researchers are simultaneously pursuing the same solutions. Summary: Autumn's news queue and focus on Circio Today's BioWorld cases point to the biological themes Circio has built its platform around: in vivo therapy, extended expression, demanding CNS delivery, and non-integrating RNA with high activity. With preclinical data showing up to 50x increased expression in the eye and 40x in the heart, as well as an active in vivo collaboration with a top-5 pharma partner in CNS, Circio's news drivers are at the intersection of these global trends. The key going forward is about who delivers the highest activity and longest expression in the tissue. It is at this intersection that the circVec platform is positioned. It is also here that several of autumn's expected data points are anticipated to give the market a better understanding of the platform's potential.Love getting such professional and good input! Excellent, yes! This case might eventually be a Nobel Prize? No negative "results" per Erik until 2030! What happens until then!? Was also enthusiastic about Aker Horizone…. This is so incredibly exciting. Still in the red, yes, but I've thoroughly familiarized myself with Circio, plus over 20 years in a pharmaceutical company, so …
- ·13 t sittenIt's been a long time since such a sell-side/post has been seen at close. It must be said to be impressive that it's doing so well here in the middle of the holiday season. I have invested in many companies/stocks, but rarely have I been in such an exciting case. It's absolutely wild how many strings they have to play on. My estimate when the week is over is approx 10kr. But I have been wrong before. Good luck to you all.I bet when it gets up to 9 again, one will realize that the sentiment has shifted and the uptrend is lasting. Eventually, we will probably also get some FOMO boost, as most know that this could quickly be 10 the year's case that materializes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt